Hashad Yehia's Insider Trades & SAST Disclosures
Hashad Yehia's most recent trade in Unity Biotechnology Inc was a trade of 20,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 8, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Hashad Yehia.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Unity Biotechnology Inc | Yehia Hashad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 60,085 | 60,085 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 25,225 | 119,580 | - | 0 | Common Shares, No Par Value | |
| Bausch + Lomb Corp | Hashad Yehia | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,751 | 94,355 | - | 17.8 | 49,050 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,324 | 97,106 | - | 17.8 | 41,437 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 2,841 | 99,430 | - | 15.5 | 44,121 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 2,143 | 102,271 | - | 16.5 | 35,295 | Common Shares, No Par Value |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 63,516 | 63,516 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Bausch + Lomb Corp | Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 20,973 | 104,414 | - | 0 | Common Shares, No Par Value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges